Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nektar TherapeuticsFRA:ITH0 +0.53%44 Debt-to-Equity is 0.14 as of Mar. 2026, which is 55% below its 10-year median of 0.31. GuruFocus rates FRA:ITH0 with a GF Score™ of 44/100 and a GF Value™ of €4.91 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 967 Biotechnology companies, Nektar Therapeutics ranks better than 53.98% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nektar Therapeutics's Debt-to-Equity or its related term are showing as below:
FRA:ITH0'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6.34 Med: 0.31 Max: 73.27
Current: 0.14
During the past 13 years, the highest Debt-to-Equity Ratio of Nektar Therapeutics was 73.27. The lowest was -6.34. And the median was 0.31.
FRA:ITH0's Debt-to-Equity is ranked better than 53.98% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:ITH0: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nektar Therapeutics Debt-to-Equity Related Terms
Nektar Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nektar Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ITH0 vs PHVS, MLYS, NRIX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Nektar Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics (FRA:ITH0) has a Debt-to-Equity of 0.14 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nektar Therapeutics and its competitors. This is 55% below median its historical median of 0.31. According to the industry distribution chart, Nektar Therapeutics ranks #445 out of 967 companies in the Biotechnology industry, placing it in the top 46%.
Is Nektar Therapeutics' Debt-to-Equity too high?
Nektar Therapeutics' current Debt-to-Equity of 0.14 is 55% below median its 10-year median of 0.31. The Biotechnology industry median Debt-to-Equity is 0.16. Nektar Therapeutics' value of 0.14 is 12.5% below this industry median. Based on the distribution chart, Nektar Therapeutics ranks #445 out of 967 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nektar Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Debt-to-Equity compare to PHVS and MLYS?
According to the Biotechnology industry distribution chart, Nektar Therapeutics ranks #445 out of 967 companies for Debt-to-Equity. This puts Nektar Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Nektar Therapeutics' value of 0.14 is 12.5% below this benchmark. While the company's 10-year median is 0.31 vs. the industry median of 0.16, Nektar Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nektar Therapeutics's current Debt-to-Equity of 0.14 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nektar Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nektar Therapeutics's current Debt-to-Equity is 0.14, which is 55% below median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.91, compared to a current price of €61.00 — trading 1142.4% above its estimated fair value. The current Debt-to-Equity is 0.14, which is 55% below median its 10-year median of 0.31 and 12.5% below the Biotechnology industry median of 0.16. Nektar Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Debt-to-Equity is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?
Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued.
The current stock price of €61.00 is trading 1142.4% above its estimated GF Value™ of €4.91.
GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:ITH0:
Debt-to-Equity: 0.14 (55% below median its 10-year median of 0.31)
GF Value™: €4.91 vs. price of €61.00 (1142.4% above fair value)
Industry Position: 12.5% below the Biotechnology median (#445 of 967)
No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
44GF Score
Get the complete analysis for FRA:ITH0
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ITH0 has been successfully added to your 
